Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Common Terminology Criteria for Adverse Events

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,044 result(s) found for: Common Terminology Criteria for Adverse Events. Displaying page 1 of 53.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-004050-29 Sponsor Protocol Number: Vvax001-UMCG-02 Start Date*: 2020-03-30
    Sponsor Name:University Medical Center Groningen
    Full Title: A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia.
    Medical condition: HPV-16 induced pre malignant cervical lesions
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003284-21 Sponsor Protocol Number: 71151 Start Date*: 2020-01-13
    Sponsor Name:Radboudumc
    Full Title: Radio guided lymph node dissection in oligo metastatic prostate cancer patients; a feasibility study
    Medical condition: Patients diagnosed with prostate cancer upon prostate biopsy, who are suspected of having lymph node involvement based upon PSMA-PET/CT.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005179-41 Sponsor Protocol Number: FIL_PTCL13 Start Date*: 2014-05-27
    Sponsor Name:Fondazione Italiana Linfomi ONLUS (FIL-ONLUS)
    Full Title: ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMAS: A PHASE I-II STUDY.
    Medical condition: Newly diagnosed patients with Peripheral T-cell lymphomas including: Peripheral T-cell lymphomas not otherwise specified (PTCL-NOS), Angioimmunoblastic T-cell lymphoma (AITL) and ALK– Anaplastic la...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002452-37 Sponsor Protocol Number: IMG-7289-CTP-202 Start Date*: 2022-01-27
    Sponsor Name:Imago BioSciences Inc.
    Full Title: A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat ...
    Medical condition: Patients with Myeloproliferative Neoplasms (MPNs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001458-40 Sponsor Protocol Number: BO29159 Start Date*: 2015-05-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN® SC IN COMBINATION WITH PERJETA® AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCA...
    Medical condition: HER2−POSITIVE METASTATIC OR LOCALLY RECURRENT ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) GB (Completed) IT (Completed) ES (Completed) HU (Completed) BE (Completed) DE (Completed) FR (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004623-36 Sponsor Protocol Number: MEGALiT1901 Start Date*: 2019-11-29
    Sponsor Name:Uppsala University Hospital
    Full Title: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial – a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targete...
    Medical condition: In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001364-30 Sponsor Protocol Number: D20180177 Start Date*: 2019-11-04
    Sponsor Name:Assistance Publique- Hôpitaux de Paris
    Full Title: Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003779-32 Sponsor Protocol Number: NL77171.091.21 Start Date*: 2021-09-27
    Sponsor Name:Radboud University Medical Center
    Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study).
    Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003778-29 Sponsor Protocol Number: CIFRA Start Date*: 2019-03-06
    Sponsor Name:Istituto Nazionale Tumori G. Pascale
    Full Title: Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / V
    Medical condition: advanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / V
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-005215-29 Sponsor Protocol Number: 03-CoFactor Start Date*: 2005-06-03
    Sponsor Name:ADVENTRX Pharmaceuticals Inc
    Full Title: A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU versus Leucovorin and 5-FU in Subjects with Metastatic Colo...
    Medical condition: Metastatic Colorectal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10052358 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003998-96 Sponsor Protocol Number: AXAGIST Start Date*: 2019-04-03
    Sponsor Name:Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie
    Full Title: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST
    Medical condition: GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003520-37 Sponsor Protocol Number: D081DC00008 Start Date*: 2014-02-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatmen...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) CZ (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006253-41 Sponsor Protocol Number: DC-004 Start Date*: 2012-01-05
    Sponsor Name:The Norwegian Radium Hospital, Oslo University Hospital
    Full Title: Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanoma
    Medical condition: Malignant melanoma stage IV M1c or better
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005203-18 Sponsor Protocol Number: 110551 Start Date*: 2008-06-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous mela...
    Medical condition: MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003976-11 Sponsor Protocol Number: HSG-1-13 Start Date*: 2014-01-24
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma
    Medical condition: Metastatic gastrointestinal tract adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002620-36 Sponsor Protocol Number: 17000139BLC3001 Start Date*: 2021-05-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma...
    Medical condition: Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned) PL (Completed) BE (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023409-37 Sponsor Protocol Number: AMLSG_15-10 Start Date*: 2011-03-02
    Sponsor Name:University Hospital Ulm
    Full Title: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM...
    Medical condition: Adult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006413-33 Sponsor Protocol Number: 3206K2-104-WW Start Date*: 2008-02-14
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    Medical condition: Relapsed or refractory B-cell Non Hodgkin's Lymphoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003762-39 Sponsor Protocol Number: GOIRC–03-2019 Start Date*: 2021-03-09
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION
    Medical condition: MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000283-28 Sponsor Protocol Number: IB_2013–01 Start Date*: 2013-11-13
    Sponsor Name:Institut Bergonié
    Full Title: Efficacy and Safety of PD-0332991 in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 study
    Medical condition: Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 07:12:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA